Treatment of intractable rheumatoid arthritis with total lymphoid irradiation (TLI): immunological and clinical changes

Samuel Strober; Elizabeth M Field; Brian L Kotzin; Richard T Hoppe; Edgar C Engleman; Amir S Tanay; Henry S Kaplan

doi:10.1016/S0167-8140(83)80006-1

Back

Treatment of intractable rheumatoid arthritis with total lymphoid irradiation (TLI): immunological and clinical changes

Journal article

Peer reviewed

Treatment of intractable rheumatoid arthritis with total lymphoid irradiation (TLI): immunological and clinical changes

Samuel Strober, Elizabeth M Field, Brian L Kotzin, Richard T Hoppe, Edgar C Engleman, Amir S Tanay and Henry S Kaplan

Radiotherapy and oncology, Vol.1(1), pp.43-52

1983

DOI: 10.1016/S0167-8140(83)80006-1

PMID: 6239305

View Online

Abstract

Eleven patients with intractable rheumatoid arthritis were treated with total lymphoid irradiation in a feasibility study. The mantle and the inverted Y fields were treated successively to a cumulative dose of 2000 rads. Nine of eleven patients showed at least a 35% improvement in three of four clinical parameters by six months and continued to maintain at least this level of improvement at their last observation points (13–28 months after TLI). There was a marked decrease in the percentage of total T cells and Leu-3 cells (helper), but an increase in the percentage of Leu-2 cells (suppressor/cytotoxic), resulting in a dramatic increase in the Leu-2/Leu-3 ratio. There was also a decrease in response to PHA, Con A and MLR.

TLI

Immunosuppression

Rheumatoid arthritis

Details

Title: Subtitle: Treatment of intractable rheumatoid arthritis with total lymphoid irradiation (TLI): immunological and clinical changes
Creators: Samuel Strober - Division of Immunology, Department of Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, U.S.A
Elizabeth M Field - Division of Immunology, Department of Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, U.S.A
Brian L Kotzin - Division of Immunology, Department of Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, U.S.A
Richard T Hoppe - Division of Immunology, Department of Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, U.S.A
Edgar C Engleman - Division of Immunology, Department of Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, U.S.A
Amir S Tanay - Division of Immunology, Department of Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, U.S.A
Henry S Kaplan - Division of Immunology, Department of Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, U.S.A
Resource Type: Journal article
Publication Details: Radiotherapy and oncology, Vol.1(1), pp.43-52
DOI: 10.1016/S0167-8140(83)80006-1
PMID: 6239305
NLM abbreviation: Radiother Oncol
ISSN: 0167-8140
eISSN: 1879-0887
Publisher: Elsevier Ireland Ltd
Language: English
Date published: 1983
Academic Unit: Immunology; Internal Medicine
Record Identifier: 9984094762002771

Metrics

9 Record Views